Regulation of Peripheral Blood Count by Benralizumab
Treatment with benralizumab in CSU decreased eos% significantly. The
averages (min., max.) of eos% at baseline, post-placebo visit, and
4-weeks after the third benralizumab dose were 3.8 (0, 10), 3 (0.2,
6.3), and 0 (0, 0.2), respectively. Significant differences were
observed immediately after the first dose of benralizumab (visit 3)
compared to baseline (visit 1) (mean difference=3.7, p=0.0002)
(Table 2 & S-Figure 1 ). These differences persisted 8-weeks
after the last benralizumab dose (Visit 6) and were seen for responders
as well as non-responders.